Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
10.20
-0.34 (-3.23%)
Nov 21, 2024, 1:14 PM EST - Market open
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock have an average target of 21.56, with a low estimate of 11 and a high estimate of 26. The average target predicts an increase of 111.37% from the current stock price of 10.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for YMAB stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 2 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 2 | 2 | 2 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +125.49% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +115.69% | Nov 15, 2024 |
| Wedbush | Wedbush | Buy Reiterates $23 | Buy | Reiterates | $23 | +125.49% | Sep 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | +96.08% | Sep 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $20 | Buy | Initiates | $20 | +96.08% | Aug 16, 2024 |
Financial Forecast
Revenue This Year
93.50M
from 84.82M
Increased by 10.24%
Revenue Next Year
112.40M
from 93.50M
Increased by 20.21%
EPS This Year
-0.66
from -0.49
EPS Next Year
-0.55
from -0.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 100.3M | 124.6M | 134.4M | ||
| Avg | 93.5M | 112.4M | 121.3M | ||
| Low | 86.2M | 100.0M | 106.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 18.3% | 33.3% | 19.6% | ||
| Avg | 10.2% | 20.2% | 7.9% | ||
| Low | 1.6% | 7.0% | -5.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.54 | -0.26 | -0.19 |
| Avg | -0.66 | -0.55 | -0.72 |
| Low | -0.81 | -1.00 | -1.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.